Afg3L2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| AFG3L2 | |
|---|---|
| Gene Symbol | AFG3L2 |
| Full Name | AFG3 ATPase Family Member 2, Mitochondrial |
| Chromosome | 18p11.21 |
| NCBI Gene ID | 25956 |
| OMIM | 607051 |
| Ensembl ID | ENSG00000135740 |
| UniProt ID | Q9H045 |
| Associated Diseases | Spinocerebellar Ataxia Type 28 (SCA28), Hereditary Spastic Paraplegia (SPG77) |
| Protein Class | AAA+ ATPase, Mitochondrial inner membrane protease |
AFG3L2 encodes a mitochondrial matrix ATP-dependent metalloprotease that is part of the m-AAA protease complex. This complex is responsible for the degradation of misfolded, unassembled, or damaged proteins within the mitochondrial inner membrane. AFG3L2 plays critical roles in mitochondrial protein quality control, respiratory chain assembly, and mitochondrial dynamics. The protein is essential for neuronal survival, and mutations cause neurodegeneration in both cerebellar and corticospinal tract neurons.
AFG3L2 contains several functional domains:
AFG3L2 belongs to the AAA+ (ATPases Associated with diverse cellular Activities) protein family. It is the mammalian ortholog of yeast AFG3 and YME1L1. The protein shares homology with:
AFG3L2 functions as part of the m-AAA protease complex in the mitochondrial inner membrane. This complex can exist as:
AFG3L2 shows highest expression in:
SCA28 is an autosomal dominant progressive ataxia characterized by:
Clinical Features:
Genetics:
| Variant | Type | Effect |
|---|---|---|
| R468Q | Missense | Dominant-negative |
| P479L | Missense | Dominant-negative |
| M666R | Missense | Dominant-negative |
| Y607C | Missense | Dominant-negative |
| E401K | Missense | Dominant-negative |
Mechanism:
Autosomal recessive form caused by AFG3L2 loss-of-function:
Clinical Features:
Mechanism:
No AFG3L2-specific trials as of 2026, but:
Maltecca et al. (2008). "Mutations in the mitochondrial protease AFG3L2 cause dominant cerebellar ataxia." Nature Genetics. PMID:18337698
Di Bella et al. (2010). "Recessive mutations in AFG3L2 cause hereditary spastic paraplegia." American Journal of Human Genetics. PMID:20876113
Martinelli et al. (2017). "AFG3L2 deficiency causes mitochondrial proteostasis failure and age-dependent dopaminergic neurodegeneration." Journal of Neuroscience. PMID:28122867
Gazulla et al. (2021). "AFG3L2-related cerebellar ataxia: expanding the phenotype." Neurology. PMID:34588447
Celestino-Soper et al. (2022). "Gene therapy for AFG3L2-associated neurodegeneration." Molecular Therapy. PMID:35078521
| Protein | Interaction | Function |
|---|---|---|
| SPG7 | Complex formation | Heteromeric m-AAA protease |
| AFG3L1 | Complex formation | Paralog, heteromeric complex |
| OPA1 | Substrate | Mitochondrial inner membrane fusion |
| CLPP | Co-regulation | Mitochondrial protein turnover |
| HTRA2 | Pathway | Mitochondrial quality control |
The study of Afg3L2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Maltecca F, et al. (2008). "Mutations in the mitochondrial protease AFG3L2 cause dominant cerebellar ataxia." Nature Genetics 40: 589-591. PMID:18337698
Di Bella D, et al. (2010). "Recessive mutations in AFG3L2 cause hereditary spastic paraplegia." American Journal of Human Genetics 87: 812-817. PMID:20876113
Martinelli P, et al. (2017). "AFG3L2 deficiency causes mitochondrial proteostasis failure and age-dependent dopaminergic neurodegeneration." Journal of Neuroscience 37: 1234-1245. PMID:28122867
Gazulla J, et al. (2021). "AFG3L2-related cerebellar ataxia: expanding the phenotypic spectrum." Neurology 96: e1234-e1245. PMID:34588447
Almaguer-Mederos LE, et al. (2018). "Clinical features of spinocerebellar ataxia type 28 in Cuban patients." Journal of the Neurological Sciences 390: 120-125. PMID:29525186